To test the potential involvement of the SDF-1α/CXCR4 pathway on this beneficial effect mediated by linagliptin, AMD3100 (specific antagonist of the SDF-1α/CXCR4) was administered from Day 1 before stroke until this time point. This evidence concerns the gene CXCR4 and Stroke.